Silexion Launches Phase 2/3 Pancreatic Cancer Trial with First Site Activation
SLXN is trading near its 52-week low of $1.6 (0.6% above the low).
Summary
Silexion Therapeutics activated the first clinical site for its Phase 2/3 trial of SIL204 in pancreatic cancer, marking the start of patient screening and a transition to active clinical execution.
Key Events · Product Development and Regulatory · SLXN
-
First Clinical Site Activated
Tel Aviv Sourasky Medical Center (Ichilov) is now active for the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, with patient screening to begin in the coming weeks.
-
Trial Design and Scope
The study includes an initial safety run-in of ~18 patients, followed by a randomized cohort of ~166 patients across Israel and Germany, evaluating SIL204 with standard-of-care chemotherapy.
-
Financial and Listing Pressure
The company operates under a going-concern warning and must maintain a $5M minimum market value of listed securities for Nasdaq compliance; its market cap is approximately $1.7M.
-
Next Milestones
First patient dosing is anticipated after screening; additional Israeli and German sites are expected to join the program in the coming months.
Analysis · SLXN · Life Sciences
Silexion has activated its first clinical site for the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, moving from regulatory preparation to active execution. This is a defining operational milestone for a micro-cap biotech with a going-concern warning and a stock trading near its 52-week low. The trial's initiation validates the company's pipeline and could attract partnership or financing interest, but significant dilution risk remains given the company's precarious cash position and recent history of highly dilutive financings.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 36.7% of the 1046 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.78%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $1.60 to $223.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.